UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Presentations
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase
(GLS) in combination with paclitaxel (Pac) in patients (pts) with triple
negative breast cancer (TNBC).
Authors*: Angela DeMichele, James J. Harding, Melinda L. Telli, Pamela N. Munster, Rana McKay,
Othon Iliopoulos, Keith W. Orford, Mark K. Bennett, James Walter Mier, Taofeek Kunle Owonikoko,
Manish R. Patel, Richard D. Carvajal, Funda Meric-Bernstam, Jeffrey R. Infante
Abstract #: 1011
Presentation Date/Time: Sunday, June 5: 8:00 - 11:30 AM
Location: Hall A, Poster Board #116
Session: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Citation: J Clin Oncol 34, 2016 (suppl; abstr 1011)
Munster Research Interests: My clinical research interests are first-in-human early phase clinical trials of
novel compounds and alternative strategies for the treatment and prevention of cancer. I have been involved
in clinical and translational research in early phase clinical trials since 1998. As the program leader for
Development Therapeutics and the PI of a peer-reviewed basic science lab, my main focus is on translating
preclinical findings into early-stage clinical trials with extensive PK and integration of PD correlative studies
and molecular imaging for patients with advanced stage cancer. My basic research interest is centered on
the role of epigenetic modification in therapy resistance in breast cancer and epigenetic priming. In addition
to studying basic mechanisms of hormone therapy resistance, we have shown that epigenetic modification
plays a crucial role in the hormonal regulation and carcinogenesis of breast cancer.
http://cancer.ucsf.edu/people/profiles/munster_pamela.3449
*UCSF authors in bold
46